Iris Isufi MD

Associate Professor, Comprehensive Cancer Center, Yale University School of Medicine

20 York St# YaleNew Haven, CT 06510
Phone+1 203-200-4363
Fax+1 203-200-2026

Dr. Isufi is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Isufi's full profile Already have an account?

Summary

Dr. Iris Isufi is an oncology specialist based in New Haven, CT, with a focus on lymphoma, stem cell transplantation, and cellular therapies. She completed her fellowship in Hematology and Medical Oncology at Yale-New Haven Medical Center and her residency in Internal Medicine at Montefiore Medical Center. Dr. Isufi has contributed to multiple publications in esteemed journals such as The Lancet and Clinical Lymphoma, Myeloma & Leukemia, and has been involved in significant clinical trials, including acting as a Principal Investigator. Her clinical interests are demonstrated in trials involving CD20 and/or CD19 positive B-cell hematologic malignancies and mantle cell lymphoma. She was awarded the CMS Meaningful Use Stage 1 Certification in 2013.

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
Stony Brook University Health Sciences Center School of MedicineClass of 2004

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 2011 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
WITHDRAWN
PHASE1
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Start of enrollment: 2019 Apr 16
COMPLETED
PHASE1
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2017 Nov 27
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator

Publications & Presentations

PubMed

Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Jennifer L Crombie, Sairah Ahmed, Matthew J Frigault, Bradley D Hunter, M Lia Palomba
Blood. 2026-07-16
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial.
Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf
Journal of Patient-Reported Outcomes. 2026-03-13
1 citations
Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.
Ranjana H Advani, Christopher R Kelsey, Philippe Armand, Celeste M Bello, Cecil M Benitez
Journal of the National Comprehensive Cancer Network. 2026-02-01

Abstracts/Posters

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...
Iris Isufi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma
Iris Isufi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Iris Isufi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology MeetingNovember 26th, 2024
Smilow Cancer Hospital Cellular Therapies ProgramJuly 30th, 2024
Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022